Author

S. S. Chandran

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 2 Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cell type annotation· 3 Approach:experimental assay· 3 Research Focus:cell-cell communication· 2 Organism:human· 2 Assay:scRNA-seq· 2 Approach:deep learning· 1 Research Focus:differential expression· 1 Research Focus:drug response / drug discovery· 1

Frequent Co-Authors

C. A. Klebanoff· 3 shared D. A. Scheinberg· 2 shared D. Betel· 2 shared M. G. Klatt· 2 shared P. Zumbo· 2 shared A. Drilon· 1 shared A. Y. Chang· 1 shared B. M. Baker· 1 shared

Activity by Year

2019-2024 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 39 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersImmunology

C. A. Klebanoff

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

CAR-engineered lymphocyte persistence is governed by a FAS ligand/FAS auto-regulatory circuit

F. Yi, T. Cohen, N. Zimmerman, F. A. Dundar, P. Zumbo, R. Eltilib, E. J. Brophy, H. Arkin, J. Feucht, M. V. Gormally, C. S. Hackett, K. N. Kropp, I. Etxeberria, S. S. Chandran, J. H. Park, , C. A. Klebanoff

This study identifies FASLG expression patterns and shows that FAS-L/FAS auto-regulation governs CAR-T and CAR-NK cell persistence, enhancing antitumor efficacy when FAS is inhibited.

bioRxiv · Feb 26, 2024 · PreprintImmunology

Immunogenicity of a public neoantigen derived from mutated PIK3CA

S. S. Chandran, J. Ma, M. G. Klatt, F. Dundar, C. Bandlamudi, P. C. Razavi, H. Y. Wen, B. Weigelt, P. Zumbo, S. N. Fu, L. B. Banks, W. D. Bestman, A. Drilon, D. Betel, D. A. Scheinberg, , C. A. Klebanoff

The paper investigates the immunogenicity of a public neoantigen derived from mutated PIK3CA, showing it is recognized by T cells and presents a framework for immunotherapy.

bioRxiv · Apr 8, 2021 · PreprintImmunology

Identification of the targets of T cell receptor therapeutic agents and cells by use of a high throughput genetic platform

R. S. Gejman, H. F. Jones, M. G. Klatt, A. Y. Chang, C. Y. Oh, S. S. Chandran, T. Korontsvit, V. Zakahleva, T. Dao, C. A. Klebanoff, D. A. Scheinberg

This study introduces a high-throughput genetic platform to identify on- and off-targets of T cell receptor therapeutic agents using MHC-I ligands.

bioRxiv · Sep 1, 2019Cancer Biology